Skip to main content
Premium Trial:

Request an Annual Quote

Sirna Exclusively Licenses UMMS Zamore miRNA Patents

NEW YORK, May 10 (GenomeWeb News) - Sirna Therapeutics said today that it has taken an exclusive worldwide license for miRNA technology from the University of Massachusetts Medical School.

 

According to Sirna, the patents cover microRNA technology for the modulation of gene expression, and could strengthen its IP position in the miRNA market. The license is for all uses, including therapeutics, diagnostics, and research reagents, Sirna said.

 

The patents cover technology invented by UMMS scientists Phillip Zamore and Gyorgy Hutvagner, and provides methods for inhibiting small RNA function, such as microRNA function in vitro and in vivo, Sirna said. The company maintained that the patents "describe methods that can be used not only for advancing RNAi basic research, but also for developing miRNA-based therapeutics. "

 

The financial terms of the license were not disclosed.

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.